Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma
✍ Scribed by Legare, Robert D.; Gribben, John G.; Maragh, Marlon; Hermanowski-Vosatka, Anne; Roach, Sheila; Tantravahi, Ramana; Nadler, Lee M.; Gilliland, D. Gary
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 269 KB
- Volume
- 56
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
✦ Synopsis
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome (t-AML/ MDS) are being reported with increasing frequency as a complication of ABMT for Hodgkin's disease and non-Hodgkin's lymphoma. At present there is no method available to predict who is at risk or is destined to develop this nearly universally fatal disorder. We therefore investigated whether clonal growth of cells is predictive of the development of t-AML/MDS. In a patient who developed secondary AML/MDS 18 months after ABMT, X-linked clonality analysis at the human androgen receptor locus was performed on serial banked samples, and documented transition from polyclonal to clonal hematopoiesis. Clonal cells could be identified 6 months after transplant (1 year prior to the diagnosis of t-AML/MDS), at a time when there was no morphologic or clinical evidence of disease. Clonality analysis can be predictive of the development of t-AML/MDS after ABMT and may offer important insights into associated risk factors and strategies to minimize the risk of t-AML/MDS. Am.